Philippines Clinical Diagnostics Market Report and Forecast 2024-2032

Philippines Clinical Diagnostics Market Outlook

The Philippines clinical diagnostics market size is expected to grow at a CAGR of 4.8% during the forecast period of 2024-2032, driven by rising healthcare and research associated investments, along with the rising incidence of infectious diseases across the region.

Philippines Clinical Diagnostics Market Overview

Clinical diagnostics are applied across multiple healthcare domains including infectious disease testing, complete blood count tests, along with liver and renal panels. The rising prevalence of chronic diseases in Philippines has elevated the demand for clinical diagnostics drastically. Being one of the most dynamic economies in the East Asia and Pacific region, Philippines has been witnessing rapid urbanization and an influx of investments to improve the medical sector, bolstering the market growth.

Philippines clinical diagnostics market demand is driven by the increasing improvements and adoption of modern technologies to offer better services to the patients. Philippines laboratories are increasingly adopting automated and digital solutions to streamline workflows and enhance accuracy of results. In addition, rising awareness on early disease detection and implementation of numerous screening programs by public as well as private institutions is expected to drive the market growth in the forecast period.

Investments in Infrastructure Improvement to Drive the Philippines Clinical Diagnostics Market Growth

In March 2023, the Philippines administration approved 123 new infrastructure projects  worth USD 163 billion. The major investment was made to enhance the research and medical infrastructure in the country, which specific emphasis on building digital connectivity and facilitating remote consultations and services across the country. It is bound to initiate multiple public-private partnerships and boost the overall economic landscape of the region.

The Philippines clinical diagnostic market share is expected to increase by increasing integration of cutting-edge technologies. In September 2023, the Consul-General of Japan and Surigao city mayor signed an agreement to grant PHP 3.5 million (USD 62k) to establish mobile x-ray system  in one of the city hospitals. The investment is a testament to rising government initiatives poised at enhancing the infrastructure and making quality services available at an affordable price.

Rising Prevalence for Artificial Intelligence

In August 2023, Japan International Cooperation Agency (JICA) and the Philippines Department of Health (DOH) collaborated to bring artificial intelligence (AI) Computer Aided Detection  (CAD) to allow early tuberculosis diagnosis, and eventually help in disease prevention. The latest technology, when applied on 400 suspected tuberculosis patients, led to successful diagnosis in 382 patients, implying its efficacy to analyze infectious diseases. The technology is expected to be used in the detection of other diseases as well, solidifying artificial intelligence integration, which is one of the major Philippines clinical diagnostic market trends.

Using Advanced Solutions for Better Patient Outcomes

Over the years, the incidence of cardiovascular diseases and cancer has significantly seen an upswing. Lung, breast, colon, rectum, and prostate cancers are some of the most commonly occurring cancers, affecting around 189 in 100,000 Filipinos. As a result, the demand for improved clinical diagnostics has risen. Focused on providing improved solutions to the patients, the healthcare providers and professionals have been continuously working to upscale their services. For instance, the Manila Doctors Hospital (MDH)  has adopted several quality services to enhance the quality of services. With a new cancer institute and cardiovascular center, equipped with cardiac catheterization laboratory (cath lab), coronary care unit, cardiac rehab, and heart care services, the hospital has been accredited for medical tourism as well.

Philippines Clinical Diagnostics Market Segmentation

Market Breakup by Test

• Lipid Panel

• Liver Panel

• Renal Panel

• Complete Blood Count

• Electrolyte Testing

• Infectious Disease Testing

• Other Tests

Market Breakup by Product

• Instruments

• Reagents

• Other Products

Market Breakup by End User

• Hospital Laboratory

• Diagnostic Laboratory

• Point of Care Testing

• Other End Users

Philippines Clinical Diagnostics Market Regional Analysis

The market growth can be attributed to an influx of investments from government, non-profit organizations as well as international healthcare companies. With easy availability of resources and academic talent, major MedTech companies are setting up new research facilities in the region, which is poised to boost the Philippines clinical diagnostics market growth in the forecast period. In addition, the growing incidence of geriatric population and a heightened focus on preventing infectious diseases is a notable market driver. In addition, other regions such as Baguio City and Central Luzon are also witnessing expedited market growth, owing to increasing infrastructure improvements.

Philippines Clinical Diagnostics Market: Competitor Landscape

In February 2023, Siemens Healthineers and Unilabs  announced EUR 200 million worth collaboration, wherein Unilabs acquired around 400 laboratory analysers to improve their infrastructure and facilitate improved diagnostic services to the consumers. The market has been witnessing a significant boost in merger related activities, with several companies pushing their boundaries to expand their product portfolios. Heightened focus on sustainability and making high-end technology accessible and affordable is a major market trend being adopted by key companies.

The key features of the Philippines clinical diagnostics market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

• Abbott

• ARUP Laboratories

• OPKO Health, Inc.

• Bioscientia Healthcare GmbH

• Charles River Laboratories

• NeoGenomics Laboratories

• Genoptix, Inc.

• Healthscope

• The Laboratory Glassware Co.

• Laboratory Corporation of America Holdings

• Fresenius Medical Care AG and Co. KGaA

• QIAGEN

• Quest Diagnostics Incorporated

• Siemens Healthcare Private Limited

• Tulip Diagnostics (P) Ltd.

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Highlights of the Report